[1]
|
董钊, 王晓琳, 何绵旺, 等. 中国偏头痛诊治指南(2022版) [J]. 中国疼痛医学杂志, 2022, 28(12): 881-898.
|
[2]
|
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, Regional, and Na-tional Incidence, Prevalence, and Years Lived with Disability for 354 Diseases and Injuries for 195 Countries and Terri-tories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1789-1858.
https://doi.org/10.1016/S0140-6736(18)32279-7
|
[3]
|
GBD 2016 Headache Collaborators (2018) Global, Regional, and National Burden of Migraine and Tension-Type Headache, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17, 954-976. https://doi.org/10.1016/S1474-4422(18)30322-3
|
[4]
|
叶深琼, 王相明, 张月辉. 偏头痛发病机制的研究进展[J]. 医学综述, 2020, 26(6): 1086-1091.
|
[5]
|
张威, 章梅玲, 褚佳育. 针刺、推拿联合盐酸氟桂利嗪胶囊对偏头痛患者疼痛改善程度及脑血流灌注的影响[J]. 新中医, 2021, 53(21): 193-197.
|
[6]
|
Ashina, M. (2020) Migraine. New England Journal of Medicine, 383, 1866-1876.
https://doi.org/10.1056/NEJMra1915327
|
[7]
|
Moskowitz, M.A., Reinhard, J.J., Romero Jr., J., Melamed, E. and Pettibone, D.J. (1979) Neurotransmitters and the Fifth Cranial Nerve: Is There a Relation to the Headache Phase of Mi-graine? Lancet, 314, 883-885.
https://doi.org/10.1016/S0140-6736(79)92692-8
|
[8]
|
王雅娟, 肖哲曼. 偏头痛三叉神经血管学说的研究进展[J]. 卒中与神经疾病, 2022, 29(5): 491-496.
|
[9]
|
Moskowitz, M.A. (1984) The Neurobiology of Vascular Head Pain. Annals of Neurology, 16, 157-168.
https://doi.org/10.1002/ana.410160202
|
[10]
|
Peters, G. L. (2019) Migraine Overview and Summary of Current and Emerging Treatment Options. American Journal of Managed Care, 25, S23-S34.
|
[11]
|
Negro, A. and Martelletti, P. (2021) Novel Synthetic Treatment Options for Migraine. Expert Opinion on Pharmacotherapy, 22, 907-922. https://doi.org/10.1080/14656566.2020.1862793
|
[12]
|
Edvinsson, L. (2022) Calcitonin Gene-Related Peptide (CGRP) Is a Key Molecule Released in Acute Migraine Attacks—Successful Translation of Basic Science to Clinical Practice. Journal of Internal Medicine, 292, 575-586.
https://doi.org/10.1111/joim.13506
|
[13]
|
Moreno-Ajona, D., Chan, C., Villar-Martínez, M.D. and Goadsby, P.J. (2019) Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review. Headache, 59, 3-19. https://doi.org/10.1111/head.13582
|
[14]
|
Castro, M.E., Pascual, J., Romón, T., et al. (1997) Differential Dis-tribution of [3H]Sumatriptan Binding Sites (5-HT1B, 5-HT1D and 5-HT1F Receptors) in Human Brain: Focus on Brain-stem and Spinal Cord. Neuropharmacology, 36, 535-542. https://doi.org/10.1016/S0028-3908(97)00061-0
|
[15]
|
Villalón, C.M. and Van Den Brink, A.M. (2017) The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and Its Relevance to the Design of Novel Treatments. Mini-Reviews in Medicinal Chemistry, 17, 928-938.
https://doi.org/10.2174/1389557516666160728121050
|
[16]
|
潘琪, 王运锋, 周冀英. 选择性5-HT_(1F)受体激动剂治疗偏头痛的疗效与机制[J]. 中国疼痛医学杂志, 2022, 28(9): 686-691.
|
[17]
|
Ailani, J., Burch, R.C.and Rob-bins, M.S. (2021) The American Headache Society Consensus Statement: Update on Integrating New Migraine Treat-ments into Clinical Practice. Headache, 61, 1021-1039.
https://doi.org/10.1111/head.14153
|
[18]
|
Nelson, D.L., Phebus, L.A., Johnson, K.W., et al. (2010) Preclinical Pharmacological Profile of the Selective 5-HT1F Receptor Agonist Lasmiditan. Cephalalgia, 30, 1159-1169. https://doi.org/10.1177/0333102410370873
|
[19]
|
Vila-Pueyo, M., Page, K., Murdock, P.R., et al. (2022) The Se-lective 5-HT1F Receptor Agonist Lasmiditan Inhibits Trigeminal Nociceptive Processing: Implications for Migraine and Cluster Headache. British Journal of Pharmacology, 179, 358-370. https://doi.org/10.1111/bph.15699
|
[20]
|
于生元, 陈小燕. 降钙素基因相关肽(CGRP)抗体治疗偏头痛[J]. 实用药物与临床, 2019, 22(8): 785-789.
|
[21]
|
Labastida-Ramírez, A., Rubio-Beltrán, E., Haanes, K.A., et al. (2020) Lasmiditan Inhibits Calcitonin Gene-Related Peptide Release in the Rodent Trigeminovascular System. PAIN, 161, 1092-1099.
https://doi.org/10.1097/j.pain.0000000000001801
|
[22]
|
de Vries, T., Villalón, C.M. and VanDenBrink, A.M. (2020) Pharmacological Treatment of Migraine: CGRP and 5-HT beyond the Triptans. Pharmacology & Therapeutics, 211, Ar-ticle ID: 107528.
https://doi.org/10.1016/j.pharmthera.2020.107528
|
[23]
|
Ramadan, N.M., Skljarevski, V., Phebus, L.A. and Johnson, K.W. (2003) 5-HT1F Receptor Agonists in Acute Migraine Treatment: A Hypothesis. Cephalalgia, 23, 776-785. https://doi.org/10.1046/j.1468-2982.2003.00525.x
|
[24]
|
VanderPluym, J.H., Halker, S.R., Urtecho, M., et al. (2021) Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-Analysis. JAMA, 325, 2357-2369. https://doi.org/10.1001/jama.2021.7939
|
[25]
|
Ferrari, M.D., Färkkilä, M., Reuter, U., et al. (2010) Acute Treatment of Migraine with the Selective 5-HT1F Receptor Agonist Lasmiditan—A Randomised Proof-of-Concept Trial. Cephalal-gia, 30, 1170-1178.
https://doi.org/10.1177/0333102410375512
|
[26]
|
Färkkilä, M., Diener, H.C., Géraud, G., et al. (2012) Efficacy and Tolerability of Lasmiditan, an Oral 5-HT1F Receptor Agonist, for the Acute Treatment of Migraine: A Phase 2 Random-ised, Placebo-Controlled, Parallel-Group, Dose-Ranging Study. The Lancet Neurology, 11, 405-413. https://doi.org/10.1016/S1474-4422(12)70047-9
|
[27]
|
Brandes, J.L., Klise, S., Krege, J.H., et al. (2019) Interim Results of a Prospective, Randomized, Open-Label, Phase 3 Study of the Long-Term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine (The GLADIATOR Study). Cephalalgia, 39, 1343-1357. https://doi.org/10.1177/0333102419864132
|
[28]
|
Tassorelli, C., Bragg, S., Krege, J.H., et al. (2021) Safety Find-ings from CENTURION, a Phase 3 Consistency Study of Lasmiditan for the Acute Treatment of Migraine. The Journal of Headache and Pain, 22, Article No. 132.
https://doi.org/10.1186/s10194-021-01343-2
|
[29]
|
Shapiro, R.E., Hochstetler, H.M., Dennehy, E.B., et al. (2019) Lasmiditan for Acute Treatment of Migraine in Patients with Cardiovascular Risk Factors: Post-Hoc Analysis of Pooled Results from 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials. The Journal of Headache and Pain, 20, Article No. 90.
https://doi.org/10.1186/s10194-019-1044-6
|
[30]
|
Martin, V.T., Ahmed, Z., Hochstetler, H.M., et al. (2021) Tolera-bility and Safety of Lasmiditan Treatment in Elderly Patients with Migraine: Post Hoc Analyses from Randomized Stud-ies. Clinical Therapeutics, 43, 1066-1078.
https://doi.org/10.1016/j.clinthera.2021.04.004
|
[31]
|
Amara, S.G., Jonas, V., Rosenfeld, M.G., Ong, E.S. and Ev-ans, R.M. (1982) Alternative RNA Processing in Calcitonin Gene Expression Generates mRNAs Encoding Different Polypeptide Products. Nature, 298, 240-244.
https://doi.org/10.1038/298240a0
|
[32]
|
Amara, S.G., Arriza, J.L., Leff, S.E., et al. (1985) Expression in Brain of a Messenger RNA Encoding a Novel Neuropeptide Homologous to Calcitonin Gene-Related Peptide. Science, 229, 1094-1097.
https://doi.org/10.1126/science.2994212
|
[33]
|
Goadsby, P.J., Edvinsson, L. and Ekman, R. (1988) Release of Vas-oactive Peptides in the Extracerebral Circulation of Humans and the Cat during Activation of the Trigeminovascular Sys-tem. Annals of Neurology, 23, 193-196.
https://doi.org/10.1002/ana.410230214
|
[34]
|
Durik, M., Kavousi, M., van der Pluijm, I., et al. (2012) Nucleotide Excision DNA Repair Is Associated with Age-Related Vascular Dysfunction. Circulation, 126, 468-478.
https://doi.org/10.1161/CIRCULATIONAHA.112.104380
|
[35]
|
耿彪, 于焕君, 党和勤. 等. 治疗偏头痛新型非口服药物研究进展[J]. 中国疼痛医学杂志, 2022, 28(10): 765-769.
|
[36]
|
Sacco, S., Bendtsen, L., Ashina, M., et al. (2019) European Headache Federation Guideline on the Use of Monoclonal Antibodies Acting on the Calcitonin Gene Related Peptide or Its Receptor for Migraine Prevention. The Journal of Headache and Pain, 20, Article No. 6. https://doi.org/10.1186/s10194-018-0955-y
|
[37]
|
Lipton, R.B., Dodick, D.W., Ailani, J., et al. (2019) Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA, 322, 1887-1898. https://doi.org/10.1001/jama.2019.16711
|
[38]
|
Hutchinson, S., Dodick, D.W., Treppendahl, C., et al. (2021) Ubro-gepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials. Neurology and Therapy, 10, 235-249. https://doi.org/10.1007/s40120-021-00234-7
|
[39]
|
Lipton, R.B., Blumenfeld, A., Jensen, C.M., et al. (2023) Effi-cacy of Rimegepant for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results from Three Phase 3 Randomized Clinical Trials. Cephalalgia, 43, Article ID: 3331024221141686. https://doi.org/10.1177/03331024221141686
|